COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Introduction Patients with hematological malignancies (HM) are uniquely immunocompromised and considered at high risk for COVID-19. However, data regarding the diagnosis, clinical course, treatment, and outcomes of these patients is sparse. In particular, the ability to successfully detect SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Alex, Ning, Bo, Socola, Francisco, Safah, Hana, Reynolds, Tim, Ibrahim, Moayed, Safa, Firas, Alfonso, Tina, Luk, Alfred, Mushatt, David M, Hu, Tony, Saba, Nakhle S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
203.Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330249/
http://dx.doi.org/10.1182/blood-2020-138611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330249/
http://dx.doi.org/10.1182/blood-2020-138611

Ejemplares similares